CalciMedica (NASDAQ:CALC) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

CalciMedica (NASDAQ:CALC) posted its earnings results on Thursday. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.14, Zacks reports.

CalciMedica Price Performance

NASDAQ:CALC traded up $0.14 during midday trading on Thursday, reaching $2.13. The stock had a trading volume of 16,085 shares, compared to its average volume of 43,939. The stock has a market capitalization of $28.70 million, a P/E ratio of -1.94 and a beta of 1.20. CalciMedica has a 1-year low of $1.83 and a 1-year high of $6.27. The firm’s fifty day simple moving average is $2.43 and its 200-day simple moving average is $3.19.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of CalciMedica in a report on Tuesday, March 4th.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.